Recent News

Recent News

Aug

27
2014

Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market

Lyndhurst NJ, USA and Ningbo, China, August 27, 2014 – Amerigen Pharmaceuticals Limited (“Amerigen”) and the Ningbo Menovo Pharmaceutical Co., Ltd, (“Menovo”) today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market. Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen to commercialize in the United States. Menovo will be responsible for manufacturing API and finished product whereas Amerigen will be responsible for clinical, regulatory and commercial activities in the United States. Amerigen will also provide support and assistance to Menovo in obtaining

Read more »


Aug

20
2014

Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic market.

Lyndhurst NJ, USA, August 20th, 2014 – Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic market. Under the terms of a marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is manufacturing the product at its US FDA approved and China CFDA certified oral solid dose facility in Suzhou, China. Sinochem is distributing the product under the Suzhou Amerigen label with exclusive sales rights in the People’s Republic of China. John Lowry, Amerigen’s

Read more »


Apr

03
2014

Amerigen has reached an agreement with UPM to commercially manufacture two ANDA products

April 2, 2014. Amerigen Pharmaceuticals, Inc. has reached an agreement with UPM, a division of Gregory Pharmaceutical Holdings, Inc., for UPM to commercially manufacture two ANDA products for a 10 year supply term.  In addition, the agreement allows for UPM to develop and potentially commercially supply several additional ANDA products for Amerigen over the next few years.  UPM acquired the 475,000 square foot Pfizer manufacturing facility in Bristol, Tennessee in July of 2013 and, eventually, all of these products will be made at this new facility. Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, Inc., said, “UPM has

Read more »


Mar

12
2014

Amerigen Pharmaceuticals Limited announces that its ANDA for carbidopa 25mg tablets has received final approval from the U.S. Food and Drug Administration

LYNDHURST, N.J., March 12, 2014 /PRNewswire/ — Amerigen Pharmaceuticals Limited announces that its ANDA for carbidopa 25mg tablets has received final approval from the U.S. Food and Drug Administration. The product is a generic equivalent of Valeant’s Lodosyn® and has been launched under an Amerigen Pharmaceuticals label. John Lowry, Amerigen’s President & CEO commented: “We are very pleased to receive our first ANDA approval. This product was entirely self-developed and manufactured by Amerigen and is the first ANDA approved for which Lodosyn® is the reference listed drug. We look forward to further approvals this year and transitioning our pipeline of

Read more »


Sep

27
2013

Amerigen subsidiary Suzhou Amerigen Pharmaceuticals enters into service agreement with Top Tier Multi-National Pharmaceutical Company

Lyndhurst NJ, USA, September 27th, 2013 – Amerigen Pharmaceuticals Limited today announced its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co., had entered into a service agreement with a Top Tier Multi-National Pharmaceutical Company (“The Firm”) to support various research and development projects for The Firm’s China market initiatives. Under the terms of the agreement, Amerigen will employ its analytical, formulation and clinical trial materials assets at its US FDA approved and China CFDA certified finished solid dose facility in Suzhou, China for project activities selected by The Firm. Terms of the agreement are undisclosed. John Lowry, Amerigen’s President & CEO commented:

Read more »


Sep

26
2013

Amerigen Pharmaceuticals Ltd. today announced its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co., had entered into a marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd.

Lyndhurst NJ, USA, September 26th, 2013 – Amerigen Pharmaceuticals Ltd. today announced its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co., had entered into a marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd. regarding Amerigen’s generic mecobalamin 0.5mg immediate release tablets. Under the terms of the agreement, Amerigen will manufacture the product at its US FDA approved and China CFDA certified finished solid dose facility in Suzhou, China. Sinochem is granted exclusive sales and distribution rights to the product in the People’s Republic of China in exchange for undisclosed payments to Amerigen. The first commercial shipments of the product, which

Read more »


Jul

31
2013

Amerigen Pharmaceuticals Limited announces collaboration with Forest Laboratories Inc.

Lyndhurst NJ, USA, July 31th, 2013 – Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products. Under the terms of the agreement, Amerigen will use its formulation expertise to develop a range of complex generic products and will commercialize such products in the United States. Forest will make undisclosed milestone payments to Amerigen and will receive royalties on US sales of such products. In addition, Forest will have an option to acquire rights to register and commercialize certain products in Latin America. John

Read more »


Mar

15
2012

Amerigen announces ANDA filing and BYSTOLIC® patent challenge

East Brunswick NJ, USA, March 15 th, 2012 – Amerigen Pharmaceuticals Limited today confirmed that its subsidiary Amerigen Pharmaceuticals Inc. has filed an Abbreviated New Drug Application (“ANDA”) containing a paragraph IV certification for a generic version of BYSTOLIC® with the US Food & Drug Administration (“FDA”) and is seeking approval to market its nebivolol hydrochloride tablets prior to expiration of U.S. Patent 6,545,040. On March 13th 2012, Forest Laboratories and Janssen Pharmaceutica filed suit for patent infringement against Amerigen in the District of Delaware. Based upon available information, Amerigen believes that it may be a first applicant to file

Read more »


Jan

11
2012

Amerigen Pharmaceuticals And Viwa Pharmaceutical Company Today Jointly Announce The Signing Of A Memorandum Of Understanding Setting Out Their Intention To Establish A Joint Venture To Develop And Register A Range Of Branded Generic Medicines For Sale In China

East Brunswick, NJ, USA and Hangzhou, China, January 11th, 2012 – Amerigen Pharmaceuticals Limited and VIWA Pharmaceutical Company Limited today jointly announce the signing of a memorandum of understanding (MOU) setting out their intention to establish a joint venture to develop and register a range of branded generic medicines for sale in China. It is anticipated that the products, once approved, would be manufactured at Amerigen’s SFDA and US FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party. Jonathan Embleton, Amerigen’s Chief Business Officer commented

Read more »


Jan

11
2012

Amerigen Pharmaceuticals and the Shanghai Fosun Omni Pharmaceutical Company Enter Into Collaboration Agreement for the Development of Generic Oral Controlled Release Products

East Brunswick NJ, USA and Shanghai, China, January 11th, 2012 – Amerigen Pharmaceuticals Limited (“Amerigen”) and the Shanghai Fosun Omni Pharmaceutical Co., Ltd, (“Fosun Omni”) today announced they had entered into a collaboration agreement regarding the development of generic oral controlled release products. Under the terms of the agreement, Fosun Omni will use its formulation expertise to develop products for Amerigen to commercialize in the United States and other territories. On signing the agreement, Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties on any commercialized products.

Read more »


1

2